You are here: Industry Insights > BAVENCIO

News List

EMD Serono, Pfizer Receive Breakthrough Therapy Designation, Submit Application for BAVENCIO americanpharmaceuticalreview
April 15, 2020
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer announced completion of the submission.
Merck, Pfizer terminate Bavencio head and neck cancer trial pharmatimes
March 17, 2020
Merck KGaA and Pfizer have decided to stop their Phase III JAVELIN study testing Bavencio (avelumab) as a potential treatment for certain patients with advanced head and neck cancer.
BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 06, 2020
The results of the study will be submitted for presentation at an upcoming medical congress and shared with the US Food and Drug Administration (FDA) and other health authorities.
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma drugs
May 15, 2019
FDA Approves Bavencio (avelumab) Plus Inlyta (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma.
Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial fiercepharma
March 21, 2019
Pfizer and Merck KGaA have had a rough go at broadening immuno-oncology drug Bavencio's reach……
Pfizer, Merck to terminate Phase III Bavencio study pharmatimes
January 04, 2019
Pfizer and Merck KGaA have announced that they will be terminating the Phase III JAVELIN Ovarian 100 study of Bavencio (avelumab), as the data did not support the study's initial hypothesis.
Merck/Pfizer’s Bavencio flunks second ovarian cancer trial pharmaphorum
December 25, 2018
Merck KGaA and Pfizer PD-L1 inhibitor Bavencio has missed the mark in its second ovarian cancer trial in a month, this time failing in previously-untreated patients....
Final guidance from NICE on Merck, Pfizer’s Bavencio pharmatimes
April 13, 2018
The National Institute for Health and Care Excellence has now published final guidelines endorsing Merck and Pfizer’s Bavencio as an option for patients with Merkel cell carcinoma (MCC).
A NICE yes for latest immunotherapy Bavencio pharmaphorum
March 06, 2018
NICE has recommended Merck KGaA and Pfizer’s Bavencio in previously treated metastatic Merkel Cell Carcinoma, a rare and aggressive form of skin cancer.
NICE Positive Recommendation Supports Use of Bavencio (Avelumab) for Treatment of Adults in England, firstwordpharma
March 02, 2018
NICE has issued a Final Appraisal Determination (FAD) that recommends avelumab for treating adults with metastatic Merkel Cell Carcinoma (mMCC).2

Previous page 1 2 3 Next page